

ORIGINAL ARTICLE

T. Iwata · T. Kanematsu

Etoposide enhances the lethal effect of radiation on breast cancer cells with less damage to mammary gland cells

Received: 27 March 1998 / Accepted: 14 August 1998

Abstract *Purpose:* In the present study, the cytotoxic effects of anticancer drug treatment plus radiation on breast cancer and normal mammary gland cells were investigated in vitro. *Methods:* Breast cancer and adjacent mammary gland tissue was obtained from surgically resected specimens from 13 premenopausal female patients, and was cultured. Cultured cells were treated with radiation and etoposide, and sensitivities were evaluated using an MTT assay. *Results:* In breast cancer cells, radiation alone had a cytotoxic effect. When etoposide was added, synergistic effects were achieved which were independent of the radiation dose. The cytotoxicity of etoposide against normal gland cells, however, was much the same as that against cancer cells, and no synergistic effects were observed in normal cells even when radiation was added. *Conclusions:* Radiation combined with etoposide showed lethal effects against breast cancer cells with less damage to normal mammary gland cells.

Key words Breast cancer cell · Mammary gland cell · Radiosensitivity · VP-16

Introduction

Radiation to the remaining breast tissues has been shown to be an effective treatment after breast-conserving surgery for cancer [1]. Nonetheless, local recurrence still occurs in some patients receiving this treatment [2–4], and radiation therapy has been known to induce cosmetic and functional disadvantages on the conserved breast [5, 6].

Several investigators have reported that prevention of local recurrence and prolongation of the disease-free

period after breast-conserving surgery for cancer could be achieved by adjuvant, postsurgical chemoradiation therapy [7, 8]. Etoposide, which is known as a radio-sensitive agent [9–11], has a distinctive mechanism as an inhibitor of topoisomerase II [12]. In addition, long-term oral administration of etoposide is known to be effective postsurgically [13]. However, the effects of chemoradiotherapy using etoposide on breast cancer and mammary gland tissue remain unknown.

In the present study, we examined the cytotoxic effects of etoposide and radiation on breast cancer cells and mammary gland cells in vitro.

Materials and methods

Cell cultures and cell treatments

From April 1994 to December 1996, 37 female patients with breast cancer underwent surgical treatment in our department. Among them, 19 were premenopausal and 18 were menopausal. Surgically resected tumor and mammary gland tissue from the 19 premenopausal patients was submitted for culture and histological examination. For culture, tumor and adjacent mammary tissue obtained from the same patient was mechanically minced, and cells were passed through a stainless steel mesh, centrifuged at 1500 rpm for 5 min, and washed with Hanks' balanced salt solution. After centrifugation, the supernatant was removed, cells were suspended in ASF301 (Ajinomoto Co., Tokyo), and cell viability was evaluated by dye exclusion with staining by 0.4% trypan blue.

The resected specimens were also utilized for histological examination. The tissues were fixed in 10% formalin and processed for embedding in paraffin. The paraffin-embedded specimens were sectioned at 5 µm and stained with hematoxylin and eosin. In cases with extensive spread of tumor cells into the mammary gland tissue, the cells were not entered into this study. Finally, the mammary gland cells of 13 patients were successfully cultured and were chosen for the current study. The number of cells was adjusted to 1×10^4 /ml. Cells were plated in 2.0-cm² plastic dishes, with four dishes used for each of nine treatment groups. Eight groups of cells were irradiated with an EXS-300 irradiator (Toshiba Electronic Co., Tokyo) at a dose rate of 0.4 Gy/min. Radiation doses were 1.2, 2.4, 4.8 and 9.6 Gy in both cancer and mammary gland cell groups. Four of the eight irradiated groups of cells (both cancer and mammary gland cells) were cultured with etoposide in dim light from 3 h after irradiation [10]. Cells were exposed to etoposide for 48 h. To the remaining group of both types of cells, etoposide

T. Iwata (✉) · T. Kanematsu
Department of Surgery II, Nagasaki University School
of Medicine, 1-7-1 Sakamoto, Nagasaki 852, Japan
Tel.: +81-95-849-7316; Fax: +81-95-849-7319

was administered without radiation. The concentration of etoposide was adjusted to 100 µg/ml which is ten times the peak plasma concentration following intravenous administration at of 80 mg/m² [10, 14, 15]. Control and treated cells were then incubated for 48 h at 37 °C in a humidified atmosphere containing 5% CO₂.

In a preliminary study, cells were treated with etoposide at 100, 10 and 5 µg/ml. Dose dependency of cytotoxicity at these concentrations of etoposide was not observed.

Cytotoxicity assays

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Chemical Co., St Louis, Mo.) assays based on succinate dehydrogenase (SD) inhibition were utilized [14, 15]. Briefly, 0.1 mol/l sodium succinate solution and 0.4% MTT solution were administered to control and treated cells after 48 h incubation, and then incubation was continued for 3 h. The supernatant was removed, and formazan was dissolved in 2 N KOH solution containing 50% dimethyl sulfoxide. SD activity was taken as the absorbance of formazan measured at 565 nm. Cytotoxicity against both tumor and mammary gland cells is presented as the SD activity in treated cells expressed as a percentage of that in control cells.

Statistical Analysis

Data are presented as means ± standard deviation. Cytotoxicity induced by treatments with radiation and/or etoposide were statistically analyzed by two-way factorial ANOVA.

Results

Cytotoxicity

The SD activities in tumor cells and mammary gland cells treated with etoposide and/or radiation are shown in Table 1. Etoposide exposure had a lethal effect on both tumor and mammary gland cells. There were no significant differences in SD activities between tumor and mammary gland cells treated with etoposide. There were no differences in viability between groups irradi-

ated with 1.2 Gy and those irradiated with 9.6 Gy in either cell type. Combined treatment with radiation and etoposide caused significantly lower survival in tumor cells compared with mammary gland cells treated with a corresponding dose of radiation. Intragroup analyses in both tumor and mammary gland cells showed no significant differences.

Discussion

Etoposide is known to be a radiosensitizer in some cancer cell lines [9–11]. As shown by Minehan and Bonner [10], etoposide causes radiosensitization even if it is applied 3 h after irradiation. However, sublethal damage repair is a rapid process, and thus the inhibition of repair interactions induced by etoposide would not be an entire mechanism for synergistic interaction between etoposide and radiation [11].

DNA synthesis has been shown to be inhibited by radiation [16]. Intrinsic radiosensitivity has been established as G₂M > G₁ > S, and cells in late S phase are most resistant [11]. Conversely, S phase cells are most susceptible to the lethal action of etoposide [17, 18]. Moreover, etoposide might be able to impair topoisomerase IIα which is involved in DNA repair even within the radiation-induced G₂ block [11]. Therefore, repair interaction and cytotoxic combination appear to be involved as mechanisms in the synergistic effect of etoposide and radiation [11].

In cultured mammary gland cells, including secretory cells and teat cells, the percentage of nondividing (G₀G₁) cells has been shown to increase as the cells reach confluency [19]. Moreover, it has been found that radiation causes a prolongation of the generation cycle of tumor cells while shortening the cell cycle of normal cells [20].

In the present study, the different distribution of cells sensitive to radiation and etoposide in the cell cycle between tumor and mammary gland cells in each patient might have caused differences in the lethal effect in both cell types when treated with etoposide following radiation. In conclusion, the differences in the lethal effect between tumor cells and mammary gland cells indicates that postsurgical treatment with radiation and etoposide might cause lethal effects on breast cancer cells without substantially damaging mammary gland cells.

Table 1 Comparison in succinate dehydrogenase (SD) activities in tumor cells and mammary gland cells treated with etoposide and/or radiation

Treatment	SD activity (%)	
	Tumor cells (n = 13)	Mammary gland cells (n = 13)
Nil (control)	100	100
Etoposide (100 µg/ml)	70 ± 4	73 ± 3
Radiation (Gy)		
1.2	88 ± 7	93 ± 10
2.4	88 ± 6	90 ± 7
4.8	90 ± 5	90 ± 7
9.6	91 ± 3	92 ± 2
Radiation (Gy) + etoposide (100 µg/ml)		
1.2	53 ± 7*	71 ± 5
2.4	51 ± 6*	72 ± 5
4.8	54 ± 4*	70 ± 8
9.6	48 ± 5*	84 ± 4

*P < 0.001

References

- Levitt SH (1994) The importance of locoregional control in the treatment of breast cancer and its impact on survival. *Cancer* 74: 1840–1846
- Slotman BJ, Meyer OW, Njo KH, Karim AB (1994) Importance of timing of radiotherapy in breast conserving treatment for early stage breast cancer. *Radiother Oncol* 30: 206–212
- Stotter A, Atkinson EN, Fairston BA, McNeese M, Oswald MJ, Balch CM (1989) Survival following locoregional recurrence after breast conservation therapy for cancer. *Ann Surg* 212: 166–172

4. Chauvet B, Reynaud-Bougnoix A, Calaise G, Panel N, Lansac J, Bougnoux P (1990) Prognostic significance of breast relapse after conservative treatment in node-negative early breast cancer. *Int J Radiat Oncol Biol Phys* 19: 1125–1130
5. Olivetto IA, Weir LM, Kim-Sing C, Bajdik CD, Trevisan CH, Doll CM, Lam WY, Basco VE, Jackson SM (1996) Late cosmetic results of short fractionation for breast conservation. *Radiother Oncol* 41: 7–13
6. Higgins S, Haffty BG (1994) Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. *Cancer* 73: 2175–2180
7. Overgaard M, Christensen JJ, Johansen H, Nybo-Rasmussen A, Rose C, VanderKooy P (1990) Evaluation of radiotherapy in high-risk breast cancer patients: report from Danish Breast Cancer Group (DBCG82) Trial. *Int J Radiat Oncol Biol Phys* 19: 1121–1124
8. Ragaz J, Jackson SM, Plenderleith IH, Wilson K, Basco V, Knowling M (1993) Can adjuvant radiotherapy improve the overall survival of breast cancer patients in the presence of adjuvant chemotherapy?: 10 year analysis of the British Columbia randomized trial (abstract). *Proc Am Soc Clin Oncol* 12: 60
9. Ng CE, Bussey AM, Raaphorst GP (1994) Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. *Int J Radiat Biol* 66: 49–57
10. Mineham KJ, Bonner JA (1993) The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment. *Life Sci* 53: 237–242
11. Giocanti N, Hennequin C, Balosso J, Mahler M, Favaudon V (1993) DNA repair and cell cycle interactions in radiation sensitization by topoisomerase II poison etoposide. *Cancer Res* 53: 2105–2111
12. Sullivan DM, Glisson BS, Hodges PK (1981) Proliferation dependence of topoisomerase II mediated drug action. *Biochemistry* 25: 2248
13. Martin M, Lluch A, Casado A, Santababara P, Adrover E, Valverde JJ, Lopez-Martin JA, Rodriguez-Lescure A, Azagra P, Garcia-Conde J, Diaz-Rubio E (1994) Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. *J Clin Oncol* 12: 986–991
14. Kanematsu T, Maehara Y, Matsumata T, Shirabe K, Akazawa K, Sugimachi K (1991) Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test. *Oncology* 48: 34–38
15. Merlin JL, Azzi S, Lignon D, Ramacci C, Zeghari N, Guillemin F (1992) MTT assays allow quick and reliable measurement of response of human tumour cells to photodynamic therapy. *Eur J Cancer* 28A: 1452–1458
16. Wang Y, Iliakis G (1992) Prolonged inhibition by X-rays of DNA synthesis in cells obtained by transformation of primary rat embryo fibroblasts with oncogenes H-ras and v-myc. *Cancer Res* 52: 508–514
17. Wilson WR, Whitmore GF (1981) Cell-cycle-stage specificity of 4-(9-acridinylamino) methanesulfon-m-anisidine (m-AMSA) and interaction with ionizing radiation in mammalian cell cultures. *Radiat Res* 87: 121–136
18. Estey E, Adlakha RC, Hittelman WN, Zwelling LA (1987) Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. *Biochemistry* 26: 4338–4344
19. Cifrian E, Guidry AJ, O'Brien CN, Keys JE, Marquardt WW (1994) Bovine mammary teat and ductal epithelial cell cultures. *Am J Vet Res* 55: 239–246
20. Bellamy AS, Hill BT (1984) Interactions between clinically effective antitumor drugs and radiation in experimental systems. *Biochim Biophys Acta* 738: 125–166